Phosphorus-31 MRI agents

By using a colloidal system and core-shell structure containing phosphate polymers in MRI hotspot agents, the toxicological and ecological problems of existing MRI contrast agents are solved, and the signal-to-noise ratio and biocompatibility of 31P MRI are improved. Degradable and efficient imaging effects are achieved.

CN119095901APending Publication Date: 2024-12-06UNIVERSITY OF TWENTE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380036303.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-05-09
Filing Date
2023-05-08
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing MRI contrast agents, such as gadolinium-based paramagnetic ions and hotspot agents, have toxicological and ecological concerns, and the low sensitivity and poor solubility of 31P MRI imaging agents lead to poor imaging results and difficult to degrade and encapsulate in vivo. Other items.

Method used

Using phosphate-containing polymers as 31P MRI hotspot agents, high local concentrations are achieved through localization of phosphorus-31 atoms in the polymer, and the signal-to-noise ratio and biocompatibility are improved by forming colloidal systems and core-shell structures. Used to form biodegradable MRI hotspot agents.

Benefits of technology

The signal-to-noise ratio of 31P MRI is improved, providing biocompatible and degradable MRI hotspot agents, solving the challenge of imaging agents accumulating and encapsulating other items in the body, achieving better imaging effects and environmental friendliness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095901A_ABST
    Figure CN119095901A_ABST
Patent Text Reader

Abstract

The present invention relates to the use of a P-containing polymer for measuring 31 P-MRI, wherein the P-containing polymer is selected from the group consisting of polyphosphates, polyphosphonates, poly (phosphine oxide), polyphosphazenes, polyphosphinates, polyphosphoric acid amide salts, polyphosphoric acid diamide salts, polyphosphoric acid amides, polythiophosphates and polythiophosphonates. The invention also relates to a polyphosphonate copolymer and an aqueous suspension comprising micelles of the polyphosphonate copolymer.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to a P-containing polymer for measuring 31 The invention relates to the use of P-MRI, and relates to a polyphosphonate copolymer and an aqueous suspension of micelles containing the polyphosphonate copolymer. Background Art

[0002] Magnetic resonance imaging (MRI) is an anatomical imaging technique that produces images based on the magnetic resonance properties of tissues. Unlike other techniques, such as radioactive imaging (e.g., PET) and optical imaging, MRI has no ionizing radiation and is not limited by the depth of tissue penetration. The contrast of the images can be increased by using contrast agents, which are usually based on gadolinium. Gd(III) is a paramagnetic ion that modulates the relaxation properties of water protons, making spots with high Gd concentrations appear brighter (so-called T1-weighted imaging). Such contrast agents have raised toxicological concerns following reports of gadolinium accumulation in the brain and tissues, and ecological concerns due to increased levels of gadolinium detected in rivers and oceans. Superparamagnetic iron oxide nanoparticles are alternative contrast agents, but they have also been shown to accumulate in organs; therefore, the FDA has withdrawn many iron oxide preparations.

[0003] Hotspot MRI introduces the imaging of other nuclei, such as fluorine-19, which can act as a selective "color" marker on anatomical proton images. When hotspot nuclei are detected directly, the signal from the hotspot nuclei can be quantified based on the signal-to-noise ratio of the MRI image. Hotspot MRI is effective, for example, in visualizing the processes behind cardiovascular disease and inflammatory responses, in labeling of immune cells, and in the detection of tumors. 1-7 Since hotspot agents contain no metal, they may be a solution to the problems of proton MRI contrast agents.

[0004] However, current hotspot agents are still far from ideal. 19 F MRI agents typically contain liquid perfluoroalkyl and polyfluoroalkyl substances (PFAS), which are usually formulated as nanoemulsions or nanoparticles. PFAS exhibit very high chemical stability and do not degrade in vivo. In addition, they are both hydrophobic and lipophobic; this poor solubility can lead to long-term accumulation in organs, up to several months. Such compounds are also considered to be major environmental pollutants. In addition, the presence of PFAS phases can make the co-encapsulation of additional items (such as drugs and other therapeutic molecules) challenging. Especially in emulsions, additional items can only be encapsulated in a thin surfactant layer.

[0005] Phosphorus-31 is a natural, non-radioactive NMR-active phosphorus isotope with a nuclear spin of 1 / 2 and a natural abundance of 100%. Phosphorus-31 is ubiquitous in biomolecules such as nucleic acids. However, the sensitivity of phosphorus-31 is only about 8% of that of hydrogen-1. The low sensitivity and generally very short relaxation times make it impossible to detect most biomolecules. However, 31 P MR spectroscopy can be used to monitor phosphorylation in muscle and sense cellular pH. 31 MRI scanners with P coils are readily available. 31 The low sensitivity of P-nuclei remains to develop exogenous 31 P imaging agents, as the sensitivity of imaging is lower than that of spectroscopy. Summary of the invention

[0006] It is an object of the present invention to overcome one or more of the above disadvantages, or at least to provide a useful alternative. It is another object of the present invention to provide an MRI hotspot agent that does not accumulate in the human body. It is another object of the present invention to provide a biocompatible MRI hotspot agent. It is another object of the present invention to provide a biodegradable MRI hotspot agent. It is another object of the present invention to provide an MRI hotspot agent that binds to biomolecules. 31 Another object of the present invention is to provide an MRI hotspot agent that can be used to encapsulate drugs and / or other therapeutic molecules.

[0007] In addition, the present invention provides a polymer containing P for measuring 31 The use of P MRI, preferably as a hot spot agent, wherein the P-containing polymer is selected from polyphosphates, polyphosphonates, poly(phosphine oxides), polyphosphazenes, polyphosphinates, polyphosphoamidos, polyphosphodiados, polyphosphoamides, polythiophosphates and polythiophosphonates. 31 The localization of the P atoms in the polymer provides a high local concentration of P. Furthermore, the polymers used according to the invention all contain phosphorus-31 in their polymer backbone, so that particularly high phosphorus-31 concentrations can be achieved. 31 The P MRI images may be acquired via direct imaging such as mCSSI (multi-echo chemical shift selective imaging) or RARE (rapid acquisition with relaxation enhancement), or via spectral imaging such as CSI (chemical shift imaging). Preferably, the P MRI images are acquired via direct imaging. 31 P MRI images.

[0008] Preferably, the amount of P in the polymer is at least 3 wt%, more preferably at least 5 wt%, even more preferably at least 10 wt%, most preferably at least 15 wt%.

[0009] Preferably, the P-containing polymer is contained in a colloidal system (i.e., a subdivided state, which means that the molecules or multimolecular particles dispersed in the medium have a size roughly between 1 nm and 1 μm in at least one direction, or discontinuities are found in the system at distances of this order; IUPAC, Compendium of Chemical Terminology, 2nd edition (i.e., the "Gold Book"), compiled by AD McNaught and A. Wilkinson. Blackwell Scientific Publications, Oxford (1997), Online version (2019-), authored by SJ Chalk. ISBN 0-9678550-9-8, https: / / doi.org / 10.1351 / goldbook), such as micelles dispersed in a liquid medium. Preferably, the liquid medium is water or a physiological solution. Preferably, the P-containing polymer is contained in micelles having a diameter between 1 nm and 1 μm, more preferably between 2 nm and 500 nm. In the case of non-spherical micelles, the above diameter is the maximum diameter of the particles. This ensures in particular that high concentrations 31 P core, thereby further overcoming the sensitivity problem. Colloidal systems can be easily injected into the human body and generally provide better biocompatibility than systems with larger particles.

[0010] Different P-containing polymers can be used to form such colloids. For example, the P-containing polymer may be insoluble in water. Such hydrophobic P-containing polymers can form emulsions with the help of emulsifiers. The P-containing polymer can also be water-soluble, in which case the P-containing polymer can form a colloidal system by crosslinking of polymer chains. The crosslinking can be chemical, or by physical interactions between polymer chains. The amphiphilic copolymer assembly contains at least two types of monomers. One or both monomers can be P-containing. The P-containing monomer can be relatively hydrophilic, and the other monomer can be relatively hydrophobic. If the relatively hydrophilic monomer is P-containing, the relatively hydrophobic monomer can be styrene. Alternatively, the P-containing monomer can be relatively hydrophobic, and the other monomer can be relatively hydrophilic. In this case, the hydrophilic monomer can be, for example, poly (ethylene glycol) (PEG). Alternatively, the P-containing polymer can be a copolymer of at least two P-containing monomers, wherein one monomer is relatively hydrophilic compared to another relatively hydrophobic P-containing monomer.

[0011] In aqueous solution, copolymers such as block copolymers and gradient copolymers can form core-shell micelles having a relatively hydrophobic core and a hydrophilic shell.

[0012] Importantly, the spheres of hydrophilic polymers stabilize the hydrophobic core and may stabilize other nanocarriers in the physiological environment, thus ensuring the so-called stealth effect.

[0013] Nanocarriers (such as micelles) comprising hydrophobic polymers and / or amphiphilic copolymers can additionally be used to encapsulate otherwise non-bioavailable items, such as hydrophobic drugs and other therapeutic agents.

[0014] Advantageously, the P-containing polymer is an amphiphilic polymer that forms core-shell micelles in aqueous solutions such as physiological solutions, wherein the hydrophilic shell is relatively rich in hydrophilic P-containing monomeric units. The higher mobility of polymer chains in the hydrophilic shell and the hydrophobic core has been shown to be important for 31 The signal-to-noise ratio of P MRI imaging is favorable.

[0015] Preferably, the P-containing polymer is biocompatible and / or biodegradable, wherein biodegradable means that the P-containing polymer completely decomposes into components that can be excreted by the human body within 1 year. More preferably, the P-containing polymer is biocompatible and biodegradable.

[0016] Preferably, the P-containing polymer has a T below 37°C, such as below 35°C, preferably below 30°C, more preferably below 25°C or below 20°C. g , where T is measured when the P-containing polymer is heated at 10°C / min g When injected into the body, i.e. at body temperature, such polymers are in a "liquid-like" viscous state and therefore also during MRI measurements. This has a positive influence on the longitudinal relaxation time T1 and the transverse relaxation time T2, which together with the concentration determine the signal intensity. Most preferably, the P-containing polymer has a T below 0 °C. g .

[0017] In MR spectroscopy, after a pulse flips the nuclear spins to a certain angle (usually 90°), the magnetization of the element precesses around the z-axis and simultaneously returns to its equilibrium state along the z-axis. The transverse x- and y-components of M (the total magnetization of the spins) decay to zero with a characteristic time T2. The longitudinal z-component grows back to its starting position with a time constant T1.

[0018] The longitudinal relaxation time T1 can be measured using an inversion recovery sequence (well known to those skilled in the art, for example described in: NMR in Biological Systems: From Molecules to Human, KVR Chary, Girjesh Govil, Springer, 2008). For the measurement of the transverse relaxation time T2, the Carr-Purcell-Meiboom-Gill (CPMG) sequence can be used, which is a standard sequence pre-installed on the NMR spectrometer (also described in the above publication).

[0019] The signal-to-noise ratio (SNR) in hotspot MRI depends on T1 and T2, which are times that depend on the properties of the molecule. A shorter T1 and a longer T2 generally result in a higher imaging contrast. Therefore, for an optimal signal-to-noise ratio, it is advantageous for T1 to be as short as possible and for T2 to be as long as possible.

[0020] Preferably, T1 is at most 5 seconds, such as at most 3 seconds or 2.5 seconds.Preferably, T2 is at least 0.03 seconds, such as at least 0.04 seconds or 0.045 seconds.

[0021] Preferably, the P-containing polymer has a T1 between 0.05 seconds and 5 seconds, a T2 between 0.03 seconds and 3 seconds, and wherein T1>T2; more preferably, T1 is between 0.1 seconds and 3 seconds, and T2 is between 0.04 seconds and 1.5 seconds, and wherein T1>T2; and more preferably, T1 is between 0.5 seconds and 2.5 seconds, and T2 is between 0.045 seconds and 1.5 seconds, and wherein T1>T2; wherein T1 and T2 are the longitudinal relaxation time and the transverse relaxation time calculated using a single exponential decay fit.

[0022] Preferably, the P-containing polymer 31 The chemical shift of P is higher than 4 ppm, such as higher than 6 ppm or higher than 10 ppm, thereby ensuring that the polymer is separated from endogenous background molecules such as ATP and DNA. 31 P chemical shifts are distinguishable, the latter generally having a lower chemical shift. Preferably, the chemical shift of the P-containing polymer is between 4ppm-100ppm, even more preferably between 6ppm-60ppm, still more preferably between 10ppm-50ppm, and most preferably between 20ppm-40ppm.

[0023] Preferably, the P-containing polymer is a polyphosphonate (PPn). Polyphosphonates are biocompatible polymers from the class of polyphosphates. The chemical shift of PPn can be adjusted between 10 ppm and 200 ppm to ensure that the polymer is compatible with endogenous background molecules such as ATP and DNA. 31The P chemical shifts are distinguishable. For example, 31 the chemical shift of P in ethyl-PPn is 37 ppm, and the chemical shift of P in phenyl-PPn is 22 ppm.

[0024] In addition, polymers from the polyphosphate group, such as the polyphosphonates provided in the present invention, are excellent carriers for other articles, specific hydrophobic articles such as drugs and other therapeutic molecules.

[0025] In addition, polyphosphates and their polyphosphonates are biodegradable. In addition, the degradation rate can be adjusted by adjusting the chemical composition when needed.

[0026] Preferably, the polyphosphonate is a copolymer. More preferably, the polyphosphonate is an amphiphilic copolymer. The amphiphilic copolymer contains hydrophilic monomer units and lipophilic / hydrophobic monomer units. In an aqueous solution, such polymers can form micelles with a hydrophobic core and a hydrophilic shell.

[0027] Preferably, the polyphosphonate copolymer contains at least two monomer units A and B, where

[0028] monomer unit and

[0029] monomer unit and where

[0030] R1 and R3 are each independently

[0031] a) where n > 1, preferably where 1 < n < 10; or

[0032] b) where n > 0, preferably where 0 < n < 10; or

[0033] c) where n > 0, preferably where 0 < n < 10; or

[0034] d) where n > 0, preferably where 0 < n < 10;

[0035] and where

[0036] R2 represents an optionally substituted phenyl, an optionally substituted benzyl or an optionally substituted phenethyl; and

[0037] R4 represents a straight-chain or branched C 1-6 alkyl, a straight-chain or branched C 2-6 alkenyl, a straight-chain or branched C 1-6 alkoxy, or a straight-chain or branched C 1-6 alkanoyl.

[0038] More preferably, R1 and R3 are a), wherein n=2;

[0039] R2 represents methylphenyl, dimethylphenyl, ethylphenyl, methylbenzyl or phenethyl; and R4 represents a linear or branched C 1-4 Alkyl, linear or branched C 2-4 Alkenyl, straight chain or branched C 1-4 Alkoxy, or linear or branched C 1-4 Alkanoyl.

[0040] Most preferably, R2 represents phenyl, and

[0041] R4 represents a methyl group or an ethyl group, preferably an ethyl group.

[0042] Preferably, the polyphosphonate copolymer comprises 30 mol% to 70 mol% A and 30 mol% to 70 mol% B, preferably 35 mol% to 65 mol% A and 35 mol% to 65 mol% B, most preferably 40 mol% to 60 mol% A and 40 mol% to 60 mol% B, the sum of A and B adding up to 100 mol%.

[0043] Preferably, the polyphosphonate copolymer comprises between 10 and 1000 monomer units, more preferably between 30 and 500 monomer units, and even more preferably between 50 and 400 monomer units.

[0044] Preferably, the polyphosphonate copolymer has a molecular weight (M) between 1000 g / mol and 100.000 g / mol, more preferably between 3000 g / mol and 80.000 g / mol, and even more preferably between 5000 g / mol and 60.000 g / mol. n Preferably, the polyphosphonate copolymer has a dispersity between 1.01 and 10.00, more preferably between 1.02 and 8, and even more preferably between 1.03 and 6. (M w / M n ).

[0045] Preferably, the polyphosphonate copolymer is a diblock copolymer, a conventional tapered block copolymer or a gradient copolymer. In the case of a copolymer with a hydrophilic monomer (such as monomeric unit B) and a hydrophobic monomer (such as monomeric unit A), such copolymers with the above composition form a core-shell micellar structure in an aqueous solution. In the core-shell micellar structure, the core is relatively rich in the most hydrophobic monomer, in this case monomeric unit A, and the shell is relatively rich in the most hydrophilic monomer, in this case monomeric unit B.

[0046] Core-shell micelles have the advantage that hydrophobic objects such as drugs and other therapeutic agents can be added to the core. In addition, the high mobility of hydrophilic units in the shell in particular leads to better imaging resolution.

[0047] It has proven to be particularly advantageous if the copolymer is a gradient copolymer. In this case, it is believed that a higher percentage of hydrophilic monomer units in the hydrophobic core also leads to an increased mobility of the polymer chains in the core, which has a positive effect on the relaxation times T1 and T2 and thus on the imaging resolution of the monomer units in the core. In addition, the monomer units in the shell have a higher mobility and thus a better imaging signal.

[0048] In particular, the present invention also relates to a polyphosphonate copolymer comprising two monomer units A and B, wherein

[0049] Monomer unit and

[0050] Monomer unit And among them

[0051] R1 and R3 are Where n = 2 to 4, and where

[0052] R2 represents phenyl, benzyl or phenethyl; and

[0053] R4 represents a methyl group, an ethyl group or a propyl group,

[0054] wherein the copolymer comprises 40 mol% to 60 mol% A and 60 mol% to 40 mol% B, and

[0055] Wherein the polyphosphonate copolymer is a diblock copolymer, a conventional tapered block copolymer or a gradient copolymer, preferably wherein the polyphosphonate copolymer is a gradient copolymer.

[0056] More specifically, the present invention also relates to a polyphosphonate copolymer comprising two monomer units A and B, wherein

[0057] Monomer unit and

[0058] Monomer unit And among them

[0059] R1 and R3 are Where n = 2, and where

[0060] R2 represents a phenyl group;

[0061] R4 represents an ethyl group; and

[0062] wherein the copolymer comprises 40 mol% to 60 mol% A and 60 mol% to 40 mol% B, and

[0063] Wherein the polyphosphonate copolymer is a diblock copolymer, a conventional tapered block copolymer or a gradient copolymer, preferably wherein the polyphosphonate copolymer is a gradient copolymer.

[0064] Gleede et al. (Gleede, T.; Markwart, JC; Huber, N.; Rieger, E.; Wurm, FR, in: Competitive Copolymerization: Access to Aziridine Copolymers with Adjustable Gradient Strengths. Macromolecules 2019, 52 (24), 9703-9714) defined four groups of gradient structures via the r parameter (reactivity parameter), which is a common way to characterize copolymers. For statistically polymerized copolymers, these four groups are defined as:

[0065] Soft gradient of 0<Δr≤1.5

[0066] Medium gradient of 1.5<Δr≤7.5

[0067] 7.5<Δr≤25 hard gradient

[0068] 25<Δr block (block sample)

[0069] where Δr is the reactivity parameter r between monomer A and A and the reactivity parameter r of monomer B B The difference between these reactivity parameters is obtained by taking the Jaacks 11 , Frey 12 , BSL 13 Description and / or Meyer-Lowry 14 The model is calculated as the mean of at least three values; the standard deviation must be below 5%.

[0070] Preferably, the polyphosphonate copolymer is a gradient copolymer having a block (block-like) gradient, a moderate gradient or a hard gradient as defined by Gleede et al., preferably a moderate gradient or a hard gradient.

[0071] Preferably, the polyphosphonate copolymer is a gradient copolymer wherein r A Between 3.5 and 25.0 and where r B Between 0.02 and 0.5, more preferably wherein r A Between 4.0 and 24.7 and where rB Between 0.03 and 0.4, most preferably where r A Between 4.3 and 24.4 and where r B Between 0.03 and 0.25.

[0072] Shull, Interfacial activity of gradient copolymers, Macromolecules 2002, 35, 8631-8639 describes the gradient parameter λ of symmetric copolymers. The gradient parameter λ describes the length of the composition gradient relative to the entire length of the copolymer. For AB copolymers, when λ=0, the copolymer is a conventional block copolymer composed of separate blocks of A units and B units. When λ=1, the composition changes smoothly from pure A to pure B along the chain.

[0073] Preferably, the polyphosphonate copolymer is a gradient copolymer having a value λ relative to the length of the minority monomer unit as defined by Shull et al., ranging from 0.1 to 1, more preferably from 0.2 to 0.99, most preferably from 0.3 to 0.98.

[0074] The invention also relates to an aqueous suspension, preferably in physiological saline solution, comprising micelles of the polyphosphonate copolymer. Preferably, the micelles have a hydrodynamic radius R between 5 nm and 100 nm, more preferably between 6 nm and 90 nm, more preferably between 7 nm and 80 nm, as measured by DLS according to ISO 22412:2008. h .

[0075] Preferably, the PDI of the micelles is between 0.001 and 0.5, more preferably between 0.01 and 0.5, even more preferably between 0.01 and 0.2, as defined in ISO 22412:2008.

[0076] Preferably, the concentration of the micelles in the aqueous suspension is at least 1 mg / mL, more preferably at least 5 mg / mL, and most preferably at least 10 mg / mL. Higher concentrations lead to increased MRI visibility. It is particularly advantageous if the concentration of the micelles in the aqueous suspension is between 1 mg / mL and 500 mg / mL, preferably 5 mg / mL and 490 mg / mL, and more preferably 10 mg / mL and 480 mg / mL.

[0077] The present invention particularly relates to an aqueous suspension comprising micelles of a polyphosphonate copolymer, wherein the micelles have an Rh between 5 nm and 100 nm as defined in ISO 22412:2008, a PDI of 0.001-0.5 as defined in ISO 22412:2008, and a concentration between 1 mg / mL-500 mg / mL, preferably 5 mg / mL-490 mg / mL, more preferably 10 mg / mL-480 mg / mL.

[0078] Brief Description of the Figures

[0079] Figure 1 Shown are the chemical structure and schematic diagram of phenyl-co-ethylphosphonate gradient copolymer micelles.

[0080] Figure 2 Results of toxicity studies of phenyl-co-ethylphosphonate gradient copolymers are shown.

[0081] Figure 3 Figure 2 shows the structure of micelles of block copolymers of PEG and PhPPn. 1 H and 31 P MRI images.

[0082] Figure 4 The micelles of the block copolymer of PS and PEtPPn are shown in Figure 2. 1 H and 31 P MRI images.

[0083] Figure 5 The micelles of phenyl-co-ethylphosphonate gradient copolymers are shown. 1 H and 31 P MRI images.

[0084] Figure 6 MRI results of injection of micelles according to the invention in Physalis are shown.

[0085] Detailed description of the drawings

[0086] Figure 1 The chemical structure and schematic diagram of the PhPPn-grad-EtPPn copolymer and its micelles are shown.

[0087] Figure 2 The results show that different concentrations of PhPPn 30 -grad-EtPPn 30 Results of micelle and cell viability studies of monocytes, leukocytes, and granulocytes.

[0088] Figure 3 PEG 5000 -bP(PhPPn) 30MRI images of micelles, from left to right: 1 H image, and based on 31 The frequency image of P. The concentration of micelles is 40 mg / mL, and 31 The concentration of P was 3.5 mg / mL. The SNR was 7.9.

[0089] Figure 4 Shows PEtPPn 62 -b-PS 345 MRI images of micelles, from left to right: 1 H image, and based on 31 The frequency image of P. The concentration of micelles is 200 mg / mL, and 31 The concentration of P was 11 mg / mL. The SNR was 18.3.

[0090] Figure 5 Shows PhPPn 30 -grad-EtPPn 30 MRI images of micelles, from left to right: 1 H image, based on EtPPn 31 P frequency image, based on PhPPn 31 The frequency image of P, and 31 P total image. The concentration of micelles is 38 mg / mL, and 31 The concentration of P was 7.7 mg / mL. The SNR was 26.4.

[0091] Figure 6 PhPPn injected into Physalis 30 -grad-EtPPn 30 MRI images of micelles, from left to right: 1 The image of H, 31 P sum image, and display 31 P sum image is superimposed on the 1 Merged image on image of H. Arrows indicate the injection sites of micelles. Example

[0092] Material

[0093] Unless otherwise stated, solvents and chemicals were purchased from Acros Organics, Sigma Aldrich, or Fluka and used as received. All chemicals were purchased at the highest purity, dried, and stored over molecular sieves. Above, if possible. Set the resistivity to 18MΩcm -1Ultrapure water (Milli-Q, ) was used for self-assembly experiments. 2-(Benzyloxy)ethanol was obtained from ABCR, distilled from calcium hydride, and stored over molecular sieves ( and ) and placed under inert gas. DBU was purchased from Sigma Aldrich, distilled from calcium hydride, and stored over molecular sieves ( and ) and placed under inert gas. Deuterated solvents were purchased from Deutero GmbH (Kastellaun, Germany) or Merck and used as received.

[0094] method

[0095] In DMF (containing 1g-L -1 of LiBr) at 60 °C and 1 mL min -1 Size exclusion chromatography (SEC) measurements were performed at a flow rate of 1.5 % using the PSS SECcurity as an integrated instrument consisting of three PSS GRAM columns (100 / 1000 / 1000 g mol -1 ) and refractive index (R1) detectors. Calibration was performed using poly(ethylene glycol) or polystyrene standards supplied by Polymer Standards Service. SEC data were plotted using OriginPro 9 software from OriginLab Corporation.

[0096] NMR spectra were measured at 298K on a Bruker Avance III 400MHz spectrometer equipped with a PA BBO 400S1 BBF-HD-05Z SP probe. CDCl3CD2Cl2 or D2O were used as deuterated solvents. The proton spectrum was calibrated relative to the solvent signal (CDCl3: δH = 7.26ppm, CD2Cl2: δH = 5.32ppm, D2O: H = 4.79ppm). The longitudinal relaxation time T1 was measured using an inversion recovery sequence. In order to measure the transverse relaxation time T2, the Carr-Purcell-Meiboom-Gill (CPMG) sequence included in the Bruker Topspin software was used. At least 10 data points were acquired and then used for data fitting. The internal scan delay was set to 5×T1. In the case of samples in water, deuterium oxide (10% by volume) was added to the sample for locking. Data analysis was performed using Mestrelab's Mestrenova14.

[0097] Dynamic light scattering (DLS) was performed at a scattering angle of 90° and 295K at the Zetasizer laboratory in Malvern, UK to measure R h The samples were diluted with ultrapure water so that the attenuator was at steps 10-11 (automatically set by the device). Data analysis was performed using ZSxplorer 2.2.0.147 software from Malvern Panalytical.

[0098] In vertical Bruker AVANCE driven by ParaVision 5.1 and 360v3.0 respectively lll Magnetic resonance imaging (MRI) images were recorded on AVANCE NEO9.4T wide-aperture NMR spectrometers, and for 1 H operates at 400.2MHz and for 31 The P measurement was operated at a frequency of 162.0 MHz. The instrument was equipped with an active shielded gradient device (with a maximum gradient strength of 1.5 T / m and a rise time of 150 μs at 100% gradient switching) and a dual tunable 1 H / 31 The experiments were performed on a Bruker Micro Imaging Unit (Micro 2.5) with a 25-mm birdcage resonator. Due to the vertical orientation of the MRI system, all phantoms were scanned in a vertical position.

[0099] Anatomical reference images were acquired using standard FLASH or RARE (FLASH: FOV 20 × 20 mm 2 , matrix 128×128, TE 1.62ms, TR 60ms, ST 2mm, NA 1, TAcq 8 seconds; RARE: FOV 30×30mm 2 , matrix 256×256, TE 4.39 ms, TR 4 seconds, ST 0.75 mm, RARE factor 4, NA 1, TAcq 4 minutes and 16 seconds). Subsequently, by using 2D 31 P chemical shift imaging (CSI) or multi-chemoselective imaging (mCSSI) was used to detect polyphosphonates. The slices (6 mm-10 mm) for spectral imaging were placed in an axial orientation, covering most of the phantom or Physalis. 2D weighted sequential recording was performed using sine-bell acquisition. 31The PCSI data set was used to improve the spatial response function using the following parameters: flip angle, 45°; TR, 250 ms; matrix 32 × 32; data points in the spectral domain, 1024; spectral width, 6510 Hz; slice selection using 500-μs sinc3 pulses; TAcq, 8 min. The PCSI data set was acquired using an in-house developed software module based on the LabVIEW software package (National Instruments, Austin). 17 Analyze the dataset. Apply an exponential filter of 20 Hz in the spectral direction.

[0100] As previously mentioned 18 mCSSI was performed using a selective excitation frequency with a bandwidth of 913 Hz (Gaussian 3 ms): for P(PhPPn 30 -grad-EtPPn 30 )3030 is 163.0138883MHz and 162.0110640MHz, for PEG 5000 -bP(PhPPn 30 ) is 162.0107971MHz, for PEtPPn 62 -b-PS 345 It is 162.0140139 MHz (TE 6.32 ms, TR 2.5 seconds, RARE factor 32, matrix 32×32, ST 8 mm, effective spectrum bandwidth 15000 Hz, NA200, TAcq 8 minutes and 20 seconds).

[0101] Cell viability - To obtain circulating immune cells, heparinized blood was removed by venipuncture of the inferior vena cava of mice. Blood was collected in heparin-filled collection tubes via a 23G cannula. Red blood cells were lysed by adding 4 times the amount of ammonium chloride buffer (pH 7.4). After incubation at room temperature for 10 minutes, the samples were centrifuged at 350 x g for 10 minutes at 20°C.

[0102] To determine 31 The cytotoxicity of P micelles was 1×10 6 Mouse immune cells were incubated with 10 μL / mL or 50 μL / mL of DMEM and incubated at 37°C for 1 hour. Then, the cells were washed and stained with CD45, CD11b, and Ly6G (all at 1:100) to distinguish monocytes (CD45 + 、CD11b + ,Ly6G - ), lymphocytes (CD45 + 、CD11b - ,Ly6G - ) and granulocytes (CD45 + 、CD11b+ ,Ly6G + ). To determine the number of dead cells, samples were placed in MACS buffer containing 1 μg / mL DAPI. Cells were gated using appropriate FSC / SSC settings and the number of DAPI cells was determined via flow cytometry.

[0103] Differential scanning calorimetry (DSC) measurements were performed using a Trios DSC 25 series thermal analysis system in the temperature range of −80 °C to 50 °C under nitrogen with a heating rate of 10 °C min -1 All glass transition temperatures (T g ) were obtained from the second heating ramp of the experiment.

[0104] Monomer synthesis

[0105] Ethylphosphonyl dichloride (EtPCl) 8

[0106] A mixture of diethyl ethylphosphonate (252.9 g, 1.521 mol) and DMF (1.3 mL) was added dropwise to refluxing thionyl chloride (305 mL, 4.2 mol). Vigorous gas evolution of ethylene chloride and sulfur dioxide indicated the progress of the reaction. After 16 hours, the gas evolution decreased. To complete the reaction, the bath temperature was increased to 120°C for 24 hours. The thionyl chloride was isolated via distillation. The crude product was fractionated twice to give the desired dichloride as a light yellow liquid (202.2 g, 100% yield, bp 40°C-42°C / 710 -2 mbar).

[0107] 1 H NMR (CDCl3, ppm): δ=2.6(dq, 2 J HP =15.0Hz, 3 J HH =7.5Hz,2H,-P-CH2-),1.4(dt, 3 J HP =30.1Hz, 3 J HH =7.5 Hz, 3H, methyl).

[0108] 31 P{H}NMR (CDCl3, ppm): δ = 53.7.

[0109] 2-Ethyl-2-oxo-1,3,2-dioxaphospholane (1)(EtPPn) 8

[0110] 400mL dry THF is added to a flame-dried three-necked round-bottom flask equipped with a magnetic stirrer and two dropping funnels, and cooled to -21 ° C. Ethylphosphonyl dichloride (153.4g, 1.04mol) is dissolved in anhydrous THF (400mL) and transferred to a dropping funnel via a flame-dried stainless steel capillary. THF (300mL) solution of anhydrous ethylene glycol (64.8g, 1.04mol) and anhydrous pyridine (165.1g, 2.08mol) is transferred to a second dropping funnel via a flame-dried stainless steel capillary. For two mixtures, the slow rate of addition is adjusted to make them roughly equal. After the addition is completed, the solution is stirred for 1 hour and kept overnight at -80 ° C to promote the precipitation of pyridine hydrochloride by-products. The precipitate is removed by filtration via a flame-dried Schlenk funnel, and the solvent is removed under reduced pressure. Two fractional distillations were performed to obtain the desired product as a colorless oil (86.3 g, yield 61%, bp 61°C / 2.110 -3 mbar).

[0111] 1 H NMR (CDCl3, ppm): δ=4.6-4.0(m,4H,-CH2-CH2-),1.9(dq, 2 J HP =18.3Hz, 3 J HH =7.8Hz,2H,-P-CH2-),1.1(m,3H,-CH3).

[0112] 31 P{H}NMR (CDCl3, ppm): δ=52.5.

[0113] Methylphosphonyl chloride (MePCl) 9

[0114] A mixture of dimethyl methylphosphonate (114.5 g, 0.92 mol) and DMF (0.9 mL) was added dropwise to refluxing thionyl chloride (160 mL, 2.2 mol). Vigorous gas evolution of methyl chloride and sulfur dioxide indicated the progress of the reaction. After 12 hours, the gas evolution decreased. To complete the reaction, the bath temperature was increased to 120°C for 24 hours. Thionyl chloride was separated by distillation. The crude product was fractionated twice to obtain the desired dichloride as colorless crystals (34.7 g, yield: 28%, bp. 48°C-50°C / 1·10 -3 mbar).

[0115] 1 H NMR (, ppm): δ = 2.5 (d, 2 J HP =16.4 Hz, 3H, -CH3).

[0116] 31 P{H}NMR (CDCl3, ppm): δ=43.7

[0117] 2-Methyl-1,3,2-dioxaphospholane 2-oxide (4)(MePPn) 9

[0118] 100mL dry THF is added to a flame-dried three-necked round-bottom flask equipped with a magnetic stirrer and two dropping funnels, and cooled to -21 ° C. Methylphosphonyl dichloride (34.7g, 261mmol) is dissolved in anhydrous THF (250mL) and transferred to a dropping funnel via a flame-dried stainless steel capillary. A THF (250mL) solution of anhydrous ethylene glycol (16.2g, 261mmol) and anhydrous pyridine (41.3g, 521mmol) is transferred to a second dropping funnel via a flame-dried stainless steel capillary. For both mixtures, the slow rate of addition is adjusted to make them approximately equal. After the addition is complete, the solution is stirred for 1 hour and stored overnight at -80 ° C to promote the precipitation of pyridine hydrochloride by-products. The precipitate is removed by filtration via a flame-dried Schlenk funnel, and the solvent is removed under reduced pressure. The desired product was obtained by fractionation as colorless crystals (8.2 g, yield: 27%, bp 80°C / 1·10 -2 mbar).

[0119] 1 H NMR (CDCl3, ppm): δ=4.5-4.1(m,4H,-CH2-CH2-),1.6(d, 3 J HP =17.6 Hz, 3H, -CH3).

[0120] 31 P{H}NMR (CDCl3, ppm): δ = 48.7.

[0121] 2-Phenyl-1,3,2-dioxaphospholane 2-oxide (PhPPn)

[0122] According to the improved literature scheme 9PhPPn was carried out. 100 mL of dry THF was added to a flame-dried three-necked round-bottom flask equipped with a magnetic stirrer and two dropping funnels, and cooled to -21 ° C. Phenylphosphonyl dichloride (50.8 g, 260 mmol) was dissolved in anhydrous THF (250 mL) and transferred to a dropping funnel via a flame-dried stainless steel capillary. A THF (250 mL) solution of anhydrous ethylene glycol (16.2 g, 260 mmol) and anhydrous pyridine (41.2 g, 521 mmol) was transferred to a second dropping funnel via a flame-dried stainless steel capillary. For the two mixtures, the slow rate of addition was adjusted to make them approximately equal. After the addition was completed, the solution was stirred for 1 hour and stored overnight at -80 ° C to promote the precipitation of pyridine hydrochloride by-products. The precipitate was removed by filtration through a flame-dried Schlenk funnel, and the solvent was removed under reduced pressure. The desired product was obtained by fractionation as a colorless solid (34.3 g, yield: 71%, bp 113°C-115°C / 1·10 -3 mbar).

[0123] 1 H NMR (CDCl3, ppm): δ=7.8 (dd, 4 J HP =14.2Hz, 3 J HH =6.9 Hz, 2H, ortho position of aromatic proton), 7.6-7.4 (m, 3H, meta and para positions of aromatic proton), 4.8-4.3 (m, 4H, -O-CH2-CH2-O-)

[0124] 31 P{H}NMR (CDCl3, ppm): δ = 36.0.

[0125] Example 1: PPn gradient copolymer micelles

[0126] Synthesis of PPn Gradient Copolymers

[0127] Ring-opening polymerization catalyzed by DBU

[0128] According to the improved literature scheme 10 The polymerization reaction was carried out. The specific monomer was weighed in a flame-dried Schlenk tube, dissolved in dry benzene, and dried by freeze drying. The monomer was dissolved in anhydrous dichloromethane to a total concentration of 4 mol L -1 The initiator 2-methoxyethanol was prepared in anhydrous dichloromethane solution with a concentration of 0.2 mol L -1 Prepare a stock solution of DBU in anhydrous dichloromethane with a concentration of 0.2 mol L -1The monomer solution and catalyst solution were set to the corresponding reaction temperature (usually -10°C).

[0129] The polymerization reaction was initiated by adding the calculated volume of catalyst solution containing 3.0 equivalents of DBU relative to the initiator. -1 The polymerization reaction was terminated with excess formic acid dissolved in dichloromethane at a concentration of 1.50 %. The colorless amorphous polymer was purified by precipitation twice in cold ether and dried in vacuo. The yield ranged from 70% to 95%.

[0130] P(PhPPn n -grad-MePPn m ) :

[0131] 1 H NMR (CDCl3, ppm): δ = 7.9-7.6 (m, ortho position of aromatic protons), 7.6-7.3 (m, meta and para positions of aromatic protons), 4.4-3.9 (m, main chain -CH2-), 3.3-3.2 (m, initiator -CH3), 1.6-1.2 (m, P-CH3)

[0132] 13 C{H}NMR (CDCl3, ppm): δ=132.9 (s, broad, aromatic-C-para), 131.7 (s, broad, aromatic-C-ortho), 128.6 (s, broad, aromatic-C-meta), 126.9 (d, 1 J CP =190.9Hz), 65.4-63.7(m, width, main chain -CH2-), 11.2(d, 1 J CP =145.3Hz,P-CH3)

[0133] 31 P{H}NMR (CDC l3, ppm): δ = 32.4 (P-CH3), 19.9 (P-Ph)

[0134] P(PhPPn n -grad-EtPPn m ) :

[0135] 1 H NMR (CDCl3, ppm): δ = 7.9-7.6 (m, ortho position of aromatic protons), 7.6-7.3 (m, meta and para positions of aromatic protons), 4.4-3.9 (m, main chain -CH2-), 3.30-3.24 (s, broad, initiator -CH3), 1.9-1.5 (m, P-CH2-), 1.3-0.9 (m, P-CH2- CH3 )

[0136] 13C{H}NMR (CDCl3, ppm): δ=132.8 (s, broad, aromatic-C-para), 131.8 (s, broad, aromatic-C-ortho), 128.9-128.2 (m, aromatic-C-meta), 126.9 (d, broad, aromatic-C-ortho), 1 J CP =191.2Hz), 65.2-63.8(m, main chain -CH2-), 18.8(d, 1 J CP =142.9Hz,P-CH2-),6.4(s width,P-CH2- CH3 )

[0137] 31 P{H}NMR (CDCl3, ppm): δ = 35.2 (P-Et), 19.8 (P-Ph)

[0138] Kinetic measurements of copolymerization reactions

[0139] In order to study the incorporation behavior of different monomers during copolymerization, the polymerization monomer mixture with the initiator prepared as described above was transferred to a dry NMR tube under inert gas. This mixture was used to set all NMR parameters (such as spacers and locks) at 263K. The reaction was started by adding the calculated volume of catalyst solution (3 equivalents of DBU relative to the initiator). The NMR tube was quickly placed in the NMR spectrometer and the experiment was started.

[0140] Determination of reactivity ratio in copolymerization

[0141] Follow Jaacks 11 , Frey 12 or BSL 13 The reactivity ratio is calculated using different nonterminal models and the Meyer-Lowry 14 The reaction was performed according to the protocol of Gleede et al., and all methods used data from 0% to 70% conversion to determine reactivity values. 15 The average of at least three models was used; the standard deviation was below 5%.

[0142] For P(PhPPn-EtPPn), r A is 23.9±0.6 and r B 0.040±0.002

[0143] For P(PhPPn-MePPn), r A is 4.48±0.02 and r B 0.222±0.001

[0144] T by DSC g Measurement

[0145] PhP 30 -grad-EtPPn 30 : -20℃

[0146] PhP 30 -grad-MePPn 30 : -10℃

[0147] PhP 50 -grad-MePPn 50 : -10℃

[0148] Preparation of gradient copolymer micelles

[0149] The water-soluble gradient copolymer was dissolved in water at the desired concentration (typically 1-4 wt%), mixed by vortexing (Fisherbrand), and then sonicated in an ultrasonic bath (Branson) for 1 min to form a clear and slightly opalescent dispersion.

[0150] Alternatively, the polymer (1-4 wt% polymer relative to the final aqueous solution) is dissolved in 300 mg acetone (VWR GPR recapture, 99%) and added to ultrapure water. The solution is sonicated for one minute and stirred overnight in an open vial to remove the acetone. This procedure can be used to encapsulate hydrophobic items, such as hydrophobic drugs. In this case, the hydrophobic item is dissolved in acetone along with the desired dose of polymer.

[0151] R of micelles of copolymers with different gradients h The data of , PDI, T1 and T2 can be found in Tables 1 and 2.

[0152] Table 1. Relaxation times of gradient copolymers .

[0153]

[0154] Table 2. Relaxation times of gradient copolymers .

[0155]

[0156] The results of transverse relaxation T2 in Tables 1 and 2

[0157] It is calculated based on single index analysis of the measured data.

[0158] Figure 2 Shown with PhPPn 30 -grad-EtPPn 30Results of viability studies performed with micelles and monocytes, leukocytes, and granulocytes. The viability at different micelle concentrations was not significantly different from the control sample. Therefore, no negative effect on cell viability was observed.

[0159] Figure 3 Phenyl-co-ethylphosphonate gradient copolymer (30 phenyl units and 30 ethyl units, PhPPn 30 -grad-EtPPn 30 ) of micelles 1 H and 31 P MRI. The signals from both the phenyl-phosphonate unit and the ethyl-phosphonate unit can be distinguished based on their chemical shifts and added to the sum image to form the final MR image; better relaxation times from both monomers result in better signals.

[0160] Figure 4 The spatial localization of the imaging agent on the anatomical proton image is shown in . To obtain this image, a small amount of micelles (about 4 mg) was injected into Physalis. It can be seen that the imaging agent can be localized on the anatomical proton image.

[0161] Example 2: PEG-b-PPn block copolymer micelles

[0162] Synthesis of Block Copolymer Poly(ethylene glycol-b-PhPPn)PEG-bP(PhPPn) :

[0163] According to the improved literature scheme 10 The polymerization reaction was carried out. PhPPn monomer was weighed in a flame-dried Schlenk tube, dissolved in dry benzene, and dried by freeze drying. The monomer was dissolved in anhydrous dichloromethane to a total concentration of 4 mol L -1 The anhydrous dichloromethane solution of m-PEGno was prepared to a concentration of 0.2 mol L -1 Prepare a stock solution of DBU in anhydrous dichloromethane with a concentration of 0.2 mol L -1 The monomer solution and catalyst solution are set to the corresponding reaction temperature (usually 0°C).

[0164] The polymerization reaction was initiated by adding the calculated volume of catalyst solution containing 3.0 equivalents of DBU relative to the initiator. -1 The polymerization reaction was terminated by an excess of formic acid dissolved in dichloromethane at a concentration of 1000 Å. The colorless amorphous polymer was purified by precipitation twice in cold ether and dried in vacuo. The yield was 80% to 96%.

[0165] PEG 5000 Representative NMR data of -bP(PhPPn) :

[0166] 1 H NMR (CDCl3, ppm): δ = 7.8-7.6 (m, ortho position of aromatic protons), 7.6-7.4 (m, broad, para position of aromatic protons), 7.4-7.2 (m, broad, meta position of aromatic protons), 4.3-4.9 (m, main chain -CH2-), 3.6 (s, broad, PEG protons), 3.4 (s, initiator -CH3)

[0167] 31 P{H}NMR (CDCl3, ppm): δ=19.8

[0168] Preparation of block copolymer micelles

[0169] The water-soluble gradient copolymer was dissolved in water at the desired concentration (typically 1-4 wt%), mixed by vortexing, and then sonicated in an ultrasonic bath for 1 minute to form a clear and slightly opalescent dispersion.

[0170] Alternatively, the polymer (1-4 wt% polymer relative to the final aqueous dispersion) was dissolved in 300 mg acetone (VWR GPR recapture, 99%) and added to ultrapure water. The solution was sonicated for one minute and stirred overnight in an open vial to remove the acetone.

[0171] On the R of micelles of two different clock copolymers h The data of , PDI, T1 and T2 can be found in Table 3.

[0172] Table 2. Relaxation times of polyphenylphosphonate-b-polyethylene glycol

[0173]

[0174] Example 3: PEtPPn-b-PS colloid

[0175] Synthesis of PEtPPn-b-PS 19

[0176] A representative procedure for the synthesis of PEtPn macro-CTA is described: Ethyl vinylphosphonate (1 g, 7.35 mmol, 60 equiv) and 2-cyano-5-hydroxypentanal-2-yl dodecyl trithiocarbonate (48 mg, 0.123 mmol, 1 equiv) were dissolved in anhydrous dichloromethane (1.83 mL) in an oven-dried 4 mL vial equipped with a magnetic stir bar. The reaction mixture was homogenized by stirring at 20 °C followed by the addition of DBU (55 μL, 55.9 mg, 0.37 mmol, 3 equiv) and the solution was stirred at room temperature for 1.5 h before being heated by the rapid addition of an excess of formic acid in dichloromethane (20 mg mL -1) The reaction mixture was quenched. The crude product was purified by precipitation three times in cold ether (-20°C) and dried under vacuum to give PEtPn 62 macro-CTA, yellow viscous liquid (0.95 g, 91%).

[0177] PEtPP 62 Representative NMR data of macro-CTA :

[0178] 1 H NMR (CDCl3, ppm): δ = 4.31-4.18 (m, main chain -CH2-); 3.34 (t, J = 7.4 Hz, initiator α-CH2-S-), 1.88-1.78 (m, P-CH2-), 1.24-1.15 (m, P-CH2- CH3 ).

[0179] 31 P{H}NMR (CDCl3, ppm): δ=35.2

[0180] Synthesis of PEtPPn via aqueous emulsion polymerization 62 -b-PS 345

[0181] PEtPn 62 Macro-CTA macroinitiator (129 mg, 0.01 mmol, 1 equivalent) and deionized water (2.73 g, 20 w / w%) were placed in a Schlenk flask and stirred until the macroinitiator was completely dissolved. A stock solution of VA-044 (10 mg mL-1) was prepared, and VA-044 (1.57 mg, 0.002 mmol, 0.3 equivalent) was added to the reaction mixture. Styrene (0.53 g, 5.11 mmol, 350 equivalent) was weighed into a separate vial and added to the solution, followed by stirring (1500 rpm) for 30 minutes. The Schlenk flask was then immersed in an ice bath, and the solution was deoxygenated with nitrogen for 30 minutes, then immersed in an oil bath at 80°C for 23 hours. Finally, the flask was placed in an ice bath and exposed to air to terminate the polymerization reaction.

[0182] 1 H NMR (CDCl3, ppm): δ = 7.2-6.2 (m, aromatic protons); 4.4-4.1 (m, EtPPn main chain); 2.0-1.1 (m, PS main chain and EtPPn side chain)

[0183] 31 P{H}NMR (CDCl3, ppm): δ=35.2

[0184] Data on Rh, PDI, T1 and T2 of the micelles of the block copolymers can be found in Table 4.

[0185] Table 4. PEtPPn- b -PS relaxation time

[0186]

[0187] Example 4: PhPPn-block-EtPPn

[0188] Synthesis of PPn Block Copolymer

[0189] Ring-opening polymerization catalyzed by DBU

[0190] According to the improved literature scheme 10 The polymerization was carried out. PhPPn and EtPPn monomers were weighed in two different flame-dried Schlenk tubes, dissolved in dry benzene, and dried by freeze drying. The monomers were dissolved in anhydrous dichloromethane to a total concentration of 4 mol L -1 The initiator 2-methoxyethanol was prepared in anhydrous dichloromethane solution with a concentration of 0.2 mol L -1 Prepare a stock solution of DBU in anhydrous dichloromethane with a concentration of 0.2 mol L -1 The monomer solution and catalyst solution were set to the corresponding reaction temperature (usually -10°C). The polymerization reaction was initiated by adding the calculated volume of the catalyst solution containing 3.0 equivalents of DBU relative to the initiator.

[0191] After 2.5 hours, the EtPPn solution was quickly added to the reaction tube. -1 The polymerization reaction was terminated by an excess of formic acid dissolved in dichloromethane at a concentration of 1000 Å. The colorless amorphous polymer was purified by precipitation twice in cold ether and dried in vacuo. The yield was 70% to 90%.

[0192] P(PhPPn n -b-EtPPn m ) :

[0193] 1 H NMR (CDCl3, ppm): δ = 7.9-7.6 (m, ortho position of aromatic protons), 7.6-7.3 (m, meta and para positions of aromatic protons), 4.4-3.9 (m, main chain -CH2-), 3.30-3.24 (s, broad, initiator -CH3), 1.9-1.5 (m, P-CH2-), 1.3-0.9 (m, P-CH2- CH3 )

[0194] 13C{H}NMR (CDCl3, ppm): δ=132.8 (s, broad, aromatic-C-para), 131.8 (s, broad, aromatic-C-ortho), 128.9-128.2 (m, aromatic-C-meta), 126.9 (d, broad, aromatic-C-ortho), 1 J CP =191.2Hz), 65.2-63.8(m, main chain -CH2-), 18.8(d, 1 J CP =142.9Hz,P-CH2-),6.4(s width,P-CH2- CH3 )

[0195] 31 P{H}NMR (CDCl3, ppm): δ = 35.2 (P-Et), 19.8 (P-Ph)

[0196] Preparation of block copolymer micelles

[0197] The water-soluble gradient copolymer was dissolved in water at the desired concentration (typically 1-4 wt%), mixed by vortexing, and then sonicated in an ultrasonic bath for 1 minute to form a clear and slightly opalescent dispersion.

[0198] Alternatively, the polymer (1-4 wt% relative to the aqueous dispersion) was dissolved in 300 mg acetone (VWR GPR recapture, 99%) and added to ultrapure water. The solution was sonicated for one minute and stirred overnight in an open vial to remove the acetone.

[0199] R of micelles of two different gradient copolymers h The data of , PDI, T1 and T2 can be found in Table 5.

[0200] Table 5. Relaxation times of block copolymers .

[0201]

[0202] literature

[0203] 1.Senders,ML;Meerwaldt,AE;van Leent,MMT;Sanchez-Gaytan,BL;van de Voort,JC;Toner,YC;Maier,A.;Klein,ED;Sullivan,NAT;Sofias,AM;

[0204] Groenen,H.;Faries,C.;Oosterwijk,RS;van Leeuwen,EM;Fay,F.;Chepurko,E.;Reiner,T.;Duivenvoorden,R.;Zangi,L.;Dijkhuizen,RM;

[0205] Nahrendorf,M.;Perez-Medina,C.;Teunissen,AJP;Fayad,ZA;Calcagno,C.;

[0206] Strijkers,GJ;Mulder,WJM,Probing myeloid cell dynamics inischaemic heart disease by nanotracer hot-spot imaging.Nat.Nanotechnol.2020,15(5),398-405.

[0207] 2.Fibgel,U.;Temme,S.;Jacoby,C.;Oerther,T.;Keul,P.;Flocke,V.;Wang,X.;Bonner,F. ;Nienhaus,F.;Peter,K.;Schrader,J.;Grandoch,M.;Keim,M.;Levkau,B.,Multi-targeted 1H / 19F MRI unmasks specific danger patterns for emergingcardiovascular disorders.Nat.Commun.2021,12(1),5847.

[0208] 3.Higuchi,M.;Iwata,N.;Matsuba,Y.;Sato,K.;Sasamoto,K.;Saido,TC,19Fand 1 H MRI detection of amyloid plaques in vivo.Nat.Neurosci.2005,8(4),527-53.

[0209] 4.Srinivas,M.Morel,PA,Ernst,LA;Laidlaw,DH,Ahrens,ET,Fluorine-19 MRI for visualization and quantification of cell migration in adiabetes model.Magn.Reson.Med.2007,58(4),725-734.

[0210] 5.Koshkina,O.Lajoinie,G.Bombelli,FBSwider,E.Cruz,LJWhite,P.Schweins,R.Dolen,Y.Dinther,EvRiessen,NKv6Rog ers,SE;Fokkink,R.Voets,IKEck,ERHv;Heerschap,A.Versluis,M.Short,CdFigdor,C.Vries,IJMdSrinivas,M.,Multicore liquid perfluorocarbon-loaded multimodal nanoparticles for stable ultrasound and 19F MRI applied to in vivo cell tracking.Adv.Fund.Mater.2019,29(19),1806485.

[0211] 6.Zhang,C.Moonshi,SS.Wang,W.Ta,HT.Han,Y.Han,FYPeng,H.6Kral,P.Rolfe,BE,Gooding,JJ.Gaus,K.Whittaker,AK,High F-ContentPerfluoropolyether-Based Nanoparticles for Targeted Detection of Breast Cancer by 19F Magnetic Resonance and Optical Imaging.ACS Nano 2018,12(9),9162-9176.

[0212] 7.Ahrens,E.T.;Bulte,J.W.M.,Tracking immune cells in vivo usingmagnetic resonance imaging.Nat.Rev.Immunol.2013,13(10),755-763.

[0213] 8.Wolf,T.;Steinbach,T.;Wurm,F.R.,A Library of Well-Defined and Water-Soluble Poly(alkyl phosphonate)s with Adjustable Hydrolysis.Macromolecules2015,48(12),3853-3863.

[0214] 9.Steinbach,T.;Ritz,S.;Wurm,F.R.,Water-Soluble Poly(phosphonate)sviaLiving Ring-Opening Polymerization.ACS Macro Letters 2014,3(3),244-248.

[0215] 10.Steinbach,T.;Ritz,S.;Wurm,F.R.,Water-Soluble Poly(phosphonate)svia Living Ring-Opening Polymerization.Acs Macro Lett.2014,3(3),244-248.

[0216] 11.Jaacks,V.,A novel method of determination of reactivity ratios inbinary and ternary copolymerizations.Die Makromolekulare Chemie:Macromolecular Chemistry and Physics 1972,161(1),161-172.

[0217] 12.Blankenburg,J.;Kersten,E.;Maciol,K.;Wagner,M.;Zarbakhsh,S.;Frey,H.,The poly(propylene oxide-co-ethylene oxide)gradient is controlled by thepolymerization method:determination of reactivity ratios by direct comparisonof different copolymerization models.Polymer Chemistry 2019,70(22),2863-2871.

[0218] 13.Beckingham,B.S.;Sanoja,G.E.;Lynd,N.A.,Simple and accuratedetermination of reactivity ratios using a nonterminal model of chaincopolymerization.Macromolecules 2015,48(19),6922-6930.

[0219] 14.Meyer,V.E.;Lowry,G.G.,Integral and differential binarycopolymerization equations.Journal of Polymer Science Part A:General Papers1965,3(8),2843-2851.

[0220] 15.Gleede,T.;Markwart,J.C.;Huber,N.;Rieger,E.;Wurm,F.R.,CompetitiveCopolymerization:Access to Aziridine Copolymers with Adjustable GradientStrengths.Macromolecules 2019,52(24),9703-9714.

[0221] 16.Ng,C.;Cousins,I.T.;DeWitt,J.C.;Gluge,J.;Goldenman,G.;Herzke,D.;Lohmann,R.;Miller,M.;Patton,S.;Scheringer,M.;Trier,X.;Wang,Z.,AddressingUrgent Questions for PFAS in the 21st Century.Environ.Sci.Technol.2021,55(19),12755-12765.

[0222] 17. U,Jacoby C,Gbdecke A,Schrader J.In vivo 2D mapping ofimpaired murine cardiac energetics in NO-induced heart failure.Magn ResonMed.2007;57:50-8.

[0223] 18. U,Temme S,Jacoby C,Oerther T,Keul P,Flocke V,Wang X, F,Nienhaus F,Peter K,Schrader J,Grandoch M,Keim M,Levkau B.Multi-targeted 1H / 19F MRI unmasks specific danger patterns for emerging cardiovasculardisorders.Nat Commun.2021;12:5847.

[0224] 19.Resendiz-Lara,D.A.;Wurm,F.R.Polyphosphonate-Based MacromolecularRAFT-CTA Enables the Synthesis of Well-Defined Block Copolymers Using Vinylmonomers;ACS Macro Lett.2021,10,10,1273-1279.

Claims

1. P-containing polymers for measurement 31 Use of P-MRI, wherein the P-containing polymer is selected from polyphosphates, polyphosphonates, poly(phosphine oxides), polyphosphazenes, polyphosphinates, polyphosphoamides, polyphosphodiamidates, polyphosphoamides, polythiophosphates and polythiophosphonates.

2. The use according to claim 1, wherein the amount of P in the polymer is at least 3 wt%, preferably at least 5 wt%, more preferably at least 10 wt%, most preferably at least 15 wt%.

3. The use according to claim 1 or 2, wherein the polymer has a T of less than 37°C, preferably less than 35°C, more preferably less than 30°C, most preferably less than 25°C or 20°C. g .

4. Use according to any one of the preceding claims, wherein the polymer has a T1 between 0.05 seconds and 5 seconds, a T2 between 0.03 seconds and 3 seconds, and wherein T1>T2; preferably, T1 is between 0.1 seconds and 3 seconds, and T2 is between 0.04 seconds and 1.5 seconds; and more preferably, T1 is between 0.5 seconds and 2.5 seconds, and T2 is between 0.045 seconds and 1.5 seconds, wherein T1 and T2 are the longitudinal relaxation time and the transverse relaxation time calculated using a single exponential decay.

5. Use according to any one of the preceding claims, wherein the P-containing polymer is a polyphosphonate.

6. The use according to claim 5, wherein the polyphosphonate is a copolymer.

7. The use according to claim 6, wherein the polyphosphonate copolymer comprises at least two monomer units A and B, wherein Monomer unit and Monomer unit And among them R1 and R3 are each independently a) where n > 1, preferably where 1 < n < 10; or b) where n > 0, preferably where 0 < n < 10; or c) where n > 0, preferably where 0 < n < 10; or d) Where n>0, preferably 0 <n<10; And among them R2 represents optionally substituted phenyl, optionally substituted benzyl or optionally substituted phenethyl; and R4 represents a straight chain or branched chain C 1-6 Alkyl, linear or branched C 2-6 Alkenyl, straight chain or branched C 1-6 Alkoxy, or linear or branched C 1-6 Alkanoyl.

8. The use according to claim 7, wherein R1 and R3 are a), wherein n=2; R2 represents methylphenyl, dimethylphenyl, ethylphenyl, methylbenzyl or phenethyl; and R4 represents a straight chain or branched C1-4 alkyl, a straight chain or branched C2-4 alkenyl, a straight chain or branched C1-4 alkoxy, or a straight chain or branched C1-4 alkanoyl, preferably R2 represents a phenyl group, and R4 represents an ethyl group.

9. The method according to claim 7, wherein the polyphosphonate copolymer comprises 30 mol% to 70 mol% A and 30 mol% to 70 mol% B, preferably 35 mol% to 65 mol% A and 35 mol% to 65 mol% B, most preferably 40 mol% to 60 mol% A and 40 mol% to 60 mol% B, the sum of A and B adding up to 100 mol%.

10. The use according to any one of claims 7 to 9, wherein the polyphosphonate copolymer is a diblock copolymer, a conventional tapered block copolymer or a gradient copolymer, preferably wherein the polyphosphonate copolymer is a gradient copolymer having a block (block-like) gradient, a medium gradient or a hard gradient as defined in Gleede et al., Macromolecules 2019, 52(24), 9703-9714, preferably a medium gradient or a hard gradient.

11. Use according to claim 10, wherein the polyphosphonate copolymer is a gradient copolymer having a value λ relative to the length of the minority monomer unit as defined by Shull, Interfacial activity of gradient copolymers, Macromolecules 2002, 35, 8631-8639, which is from 0.5 to 1, preferably from 0.6 to 1, more preferably from 0.8 to 1.

12. The use according to any one of claims 7 to 11, wherein the polyphosphonate copolymer has a molecular weight (M) between 1000 and 100.

000. n ) and a dispersion between 1.01 and 10.00 13. A polyphosphonate copolymer comprising two monomer units A and B, wherein Monomer unit and Monomer unit And among them R1 and R3 are Where n = 2 to 4, and where R2 represents phenyl, benzyl or phenethyl; R4 represents methyl, ethyl or propyl; and wherein the copolymer comprises 40 mol% to 60 mol% A and 60 mol% to 40 mol% B, and wherein the polyphosphonate copolymer is a diblock copolymer, a conventional tapered block copolymer or a gradient copolymer, preferably wherein the polyphosphonate copolymer is a gradient copolymer; preferably wherein R1 and R3 are Where n = 2, and where R2 represents a phenyl group; R4 represents an ethyl group.

14. The polyphosphonate copolymer of claim 13, wherein the polymer is a gradient copolymer, wherein r A Between 4.3 and 24.4, and where r B Between 0.03 and 0.

25.

15. An aqueous suspension comprising micelles of the polyphosphonate copolymer according to claim 13 or 14, wherein the micelles have a hydrodynamic radius R between 5 nm and 100 nm as defined in ISO 22412:2008. h , a PDI of 0.001-0.5 as defined in ISO 22412:2008, and a concentration between 1 mg / mL-500 mg / mL, preferably 5 mg / mL-490 mg / mL, more preferably 10 mg / mL-480 mg / mL.